Galectin Therapeutics Inc.
NASDAQ: GALT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joel Lewis
- Employees
- 15
- Headquarters
- Norcross, United States
- IPO year
- 2002
- Market cap
- $258.2M
- Website
- https://galectintherapeutics.com
Loading GALT…
Loading profile data…Frequently asked questions about GALT
What does Galectin Therapeutics Inc. (GALT) do?
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysacc...
Where does GALT trade?
Galectin Therapeutics Inc. (GALT) trades on the NASDAQ Capital Market.
What sector is GALT in?
Galectin Therapeutics Inc. (GALT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Galectin Therapeutics Inc.?
Joel Lewis is the chief executive officer of Galectin Therapeutics Inc. (GALT).
Where is Galectin Therapeutics Inc. headquartered?
Galectin Therapeutics Inc. is headquartered in United States.
Does GALT pay a dividend?
Galectin Therapeutics Inc. (GALT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GALT go public?
Galectin Therapeutics Inc. (GALT) completed its initial public offering in 2002.